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Abstract 
Depression is the sixth most costly health condition in the United States, and depression that 
does not respond to its first trial of antidepressant treatment adds an annual cost of $9,529 per 
person per year. Thus, choosing an effective starting antidepressant can decrease the overall cost 
of depression to society. A secondary analysis of data from the Collaborative Psychiatric 
Epidemiology Survey (CPES) was performed to create models that can predict the efficacy of 
second-generation antidepressants in treating sadness. Two sets of Principal Component 
Analyses (PCAs) and logistic regressions were performed on variables associated with patient 
demographics, clinical symptoms, past medical history, and current mental health treatments: the 
first set explored associations between symptom clusters and drug efficacy, and the second set 
created models to predict the efficacy of each of the seven antidepressants. This study found that 
when treating sadness, paroxetine and venlafaxine should be avoided in depression with low 
moods, fluoxetine should be avoided in depression with high anxiety, and sertraline should be 
avoided in depression with high levels of fatigue. In addition, the models created to predict drug 
efficacy had a mean accuracy of 84% and internal validity of 62%. Since fewer than 50% of 
patients currently respond to their first antidepressant, the use of this model could provide a 
modest improvement to choosing efficacious starting antidepressants, subsequently decreasing 
the total disease burden depression poses onto society. 
 Keywords: Mental health, medication, treatment, resistant depression, affective disorders 
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Choosing a Second-Generation Antidepressant using Demographic Characteristics and Clinical 
Symptoms of Depression 
Major Depressive Disorder (MDD) is a mood disorder characterized by persistent 
feelings of sadness or loss of interest that can be accompanied by sleep disturbances, appetite 
changes, decreased energy, difficulty with concentration, psychomotor changes, and suicidal 
ideation (American Psychiatric Association [APA], 2013). In 2015, 4.4% of the global 
population suffered from depression (World Health Organization [WHO], 2017). Together, 
depressive disorders lead to 50 million Years Lived with Disability (YLD) per year, making 
them the single largest contributor of non-fatal health loss in the world (WHO, 2017). 
Healthy People 2020 contains 42 different topics, 12 of which have been identified as 
‘Leading Health Indicators (LHI)’, a designation that signifies the topic is of particular 
importance to the health of the nation (U.S. Department of Health and Human Services, 2014). 
Mental health is designated an LHI, and within the topic of mental health, the US Department of 
Health and Human Services specifically targets two measures: 1) suicide rates and 2) the 
prevalence of Major Depressive Episodes (MDE) in adolescents. In 2007, there were 11.3 
suicides per 100,000 people. The Healthy People 2020 goal is to lower that rate to 10.2 suicides 
per 100,000 people, a 10% improvement from baseline. Similarly, in 2008, 9.3% of adolescents 
had an MDE within the past year, and the Healthy People 2020 goal is to lower that rate to 7.5%, 
a 10% improvement from baseline. 
In the United States, depressive disorders are the 6th most costly health condition. While 
there are many different treatments for depression such as psychotherapy and lifestyle 
modifications, many people choose a pharmacological approach: 50% of adults with a major 
depressive episode are treated with medication (Center for Behavioral Health Statistics and 
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Quality, 2017), and up to one-fourth of people on an antidepressant stay on the medication for at 
least 10 years (Pratt, Brody, & Gu, 201). In fact, antidepressants were the most commonly 
prescribed medication family in 2005, surpassing medications used to treat hypertension and 
hyperlipidemia (Cherry, Woodwell, & Rechtsteiner, 2007). Together, antidepressant medications 
comprise nearly one-third of the total spending on depressive disorders (Dieleman et al., 2016).  
Treatment-resistant depression, defined here as depression that does not respond to its 
first trial of antidepressants, is associated with poorer quality of life, functional status, and well-
being compared to treatment-responsive depression (Mauskopf et al., 2009). In addition to this 
increased morbidity, the risk of mortality is higher in treatment-resistant depression: 
approximately 30% of this population attempt suicide at least once in their life (Hantouche, 
Angst, & Azorin, 2010). This is twice the rate when compared to treatment-responsive 
depression, and 15 times the rate when compared to the general population (Bernal et al., 2007). 
There is also an increase in societal costs due to higher rates of healthcare utilization: this 
population has twice as many general medical visits per year than treatment-responsive 
depression (Mrazek, Hornberger, Altar, & Degtiar, 2014).  
As a result, treatment-resistant depression adds a direct and indirect annual cost of $9,529 
per person per year relative to treatment-responsive depression (Mrazek et al., 2014). In 2012, 
there were 1.9 million adults with treatment-resistant depression in the United States. Using this 
prevalence rate, treatment-resistant depression adds an additional overall societal cost of $18.1 
billion per year. This brings the total societal cost of depressive disorders to $188 billion. For 
comparison, the societal cost of cancer is $131 billion and the societal cost for diabetes is $173 
billion (Mrazek et al., 2014). Choosing an effective starting antidepressant has the potential to 
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decrease the overall societal cost of depressive disorders by almost 10%. However, there are no 
strict protocols to guide physicians in this process. 
The American Psychiatric Association (APA, 2010) guidelines state that most patients 
will have optimal responses to selective serotonin reuptake inhibitors (SSRIs), serotonin 
norepinephrine reuptake inhibitors (SNRIs), mirtazapine, or bupropion. Since meta-analyses 
designed to detect differences between the efficacies of these first-line antidepressants have 
produced mixed results (Hansen, Gartlehner, Lohr, Gaynes, & Carey, 2005; Gartlehner et al., 
2011; Brunoni, Fraguas, & Fregni, 2009; Cipriani et al., 2009), physicians are advised to pick 
antidepressants based on side effect profile, safety, tolerability, and patient preferences. Fewer 
than 50% of patients respond to their first antidepressant (Singh et al., 2017). In these patients, 
physicians can either increase the dosage, add on a second medication, or switch to a different 
antidepressant medication. This process continues until an effective medication regimen is 
achieved.  
The fact that most patients need to try multiple antidepressants before finding an effective 
regimen suggests disparate efficacies between antidepressants at the individual level despite 
comparable efficacies between antidepressants at the population level. A better understanding of 
the factors that influence an individual’s response to different antidepressants can help 
physicians better choose effective starting antidepressants for individual patients, thus increasing 
quality of life and functional status while decreasing the overall cost of depression to society.  
Purpose of Study 
The purpose of this study is to explore the impact symptom clusters have on second-
generation antidepressants’ efficacy in treating sadness and to create models that use 
demographic and clinical characteristics to predict this efficacy. Understanding how symptom 
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clusters impact drug efficacy can provide broad generalizations that guide physicians when 
choosing an antidepressant, and creating models can provide a tool that specifically tailors a 
physician’s choice of antidepressant to each patient. Together, these methods have the potential 
to decrease the overall morbidity and societal cost of depressive disorders. 
Review of Literature 
First and Second-Generation Antidepressants 
Antidepressants are broadly grouped into two categories: first-generation antidepressants 
and second-generation antidepressants. First-generation antidepressants include tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), which began appearing on 
the market in the 1950’s and 1960’s (Hillhouse & Porter, 2016). Second-generation 
antidepressants include SSRIs, SNRIs, and atypical antidepressants (e.g., bupropion, mirtazapine, 
and trazodone), which began appearing on the market in the 1980’s (Hillhouse & Porter, 2016). 
With over 25 different antidepressants across five different drug classes, it can be difficult for a 
physician to choose the optimal medication for their patients. In order to aid physicians in this 
process, many studies have been conducted to compare the different antidepressants. These 
studies have found first and second-generation antidepressants to be comparable in efficacy 
(Williams et al., 2000). However, first-generation antidepressants are associated with more 
severe adverse effects, leading to a greater discontinuation rate (Song et al., 1993; Montgomery 
et al., 1994; Williams et al., 2000). 
Efficacy. Many studies have found that first and second-generation antidepressants have 
comparable efficacies. A 1993 meta-analysis of 63 randomized-controlled trials (RCT) look at 
the efficacy and acceptability of SSRIs compared to TCAs (Song et al., 1993). This meta-
analysis found no differences in changes of the mean Hamilton-Depression Rating Scale (HAM-
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D) when subjects were treated with SSRIs versus TCAs. Similarly, a 2000 systematic review of 
315 RCTs found no difference in the efficacy between first and second-generation 
antidepressants. (Williams et al., 2000).  
Adverse effects. While there are no significant differences between the efficacies of first 
and second-generation antidepressants, studies haves shown that second-generation 
antidepressants have a more favorable side effect profile than first-generation antidepressants 
(Song et al., 1993; Montgomery et al., 1994; Williams et al., 2000). Adverse effects of TCAs 
include anticholinergic symptoms and potentially fatal cardiac arrhythmias. Side effects of 
MAOIs include dangerous and potentially lethal interactions with foods rich in tyramine (e.g., 
aged cheeses, smoked meats, and alcoholic beverages). In contrast, second-generation 
antidepressants are associated with non-life-threatening side effects, such as constipation, 
diarrhea, nausea, and sexual dysfunction (Santarsieri & Schwartz, 2015).  
One systematic review conducted in 2000 found no significant differences in 
discontinuation rates between first and second-generation antidepressants despite significantly 
different side effect profiles (Williams et al., 2000). However, many other studies have found a 
significant—albeit modest—increase in discontinuation rates of first-generation antidepressants 
compared to second-generation antidepressants due to side effects (Song et al., 1993; 
Montgomery et al., 1994; Mulrow et al., 2000; Warden et al., 2009). Due to an overall better side 
effect profile despite comparable efficacies, second-generation antidepressants are preferred over 
first-generation antidepressants. 
Second-Generation Antidepressants 
 Due to a better side effect profile, second-generation antidepressants have become the 
established first-line pharmacological treatment for depression (APA, 2010). More recent studies 
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have focused on differentiating efficacies, side effects, and tolerability of different second-
generation antidepressant medications.  
Efficacy. Results comparing the efficacy of different second-generation antidepressants 
have been mixed. A meta-analysis of 234 RCTs published in 2011 found no clinically relevant 
differences in the efficacies of second-generation antidepressants (Gartlehner et al., 2011). 
Similarly, a systematic review published in 2012 found that all SSRIs studied had comparable 
efficacies (Thaler et al., 2012).  
In contrast, a systematic review of 117 RCTs conducted from 1991 to 2007 found 
clinically relevant differences between second-generation antidepressants. Escitalopram, 
mirtazapine, sertraline, and venlafaxine were significantly more effective than fluoxetine, 
duloxetine, and paroxetine (Cipriani et al., 2009).  
A systematic review of 46 head-to-head RCTs comparing second-generation 
antidepressants had mixed results: 20 of the trials reported no statistically significant differences 
in any efficacy measure, while one study found escitalopram to be more effective than 
citalopram, and another study found paroxetine to be more effective than fluoxetine (Hansen et 
al., 2005). The authors of this systematic review found that most of the studies were sponsored 
by pharmaceutical companies, and sponsored studies were statistically more likely to favor the 
sponsor’s antidepressant. In addition, many of these studies had small sample sizes, which could 
account for differences in study results (Hansen et al., 2005). 
Adverse effects. Different drug classes of second-generation antidepressants have 
different side effects. Second-generation antidepressants fall into two main categories: activating 
drugs and sedating drugs. SSRIs, SNRIs, and bupropion are considered activating drugs while 
mirtazapine and trazodone are sedating drugs.  
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Activating drugs. As activating drugs, SSRIs, SNRIs, and bupropion can lead to 
symptoms such as increased energy, anxiety, and insomnia.  
In addition, SSRIs are commonly associated with gastrointestinal side effects, including 
nausea, vomiting, and diarrhea. These side effects are dose-dependent and usually attenuate after 
a few weeks of treatment. While sexual side effects such as a loss of libido can occur with any 
antidepressant, this effect is especially prominent with SSRIs (APA, 2013). 
SNRIs are also associated with nausea and vomiting. In addition, SNRIs can cause 
hypertension and dry mouth (APA, 2013).  
Bupropion is also associated with nausea and vomiting. Like SNRIs, hypertension and 
dry mouth are common in bupropion. However, because bupropion does not have serotonergic 
activity, it is not associated with sexual dysfunction. In addition, bupropion has been associated 
with increased seizures in those with a history of bulimia nervosa and should be avoided in this 
population (APA, 2013).  
Sedating drugs. Mirtazapine and trazodone are sedating drugs, so they are often used in 
people with insomnia or hyperactivity. In addition, mirtazapine is commonly associated with dry 
mouth and weight gain while trazodone can cause priapism, a medical emergency characterized 
by a sustained penile erection (APA, 2013). 
Serotonin syndrome. All antidepressants with serotonergic activity can cause serotonin 
syndrome, which is a medical emergency characterized by abdominal pain, diarrhea, flushing, 
sweating, hyperthermia, lethargy, mental status changes, myoclonus, rhabdomyolysis, renal 
failure, and cardiovascular shock. Thus, physicians should use caution when prescribing more 
than one antidepressant with serotonergic activity (APA, 2013). 
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Choosing an Antidepressant based on Readily Accessible Information 
 According to the APA, second-generation antidepressants like SSRIs, SNRIs, 
mirtazapine, and bupropion are all first-line pharmacological treatments for major depressive 
disorder (APA, 2010). Selection of a specific medication is nuanced and should be based on 
readily accessible information such as side effect profile, patient demographics, co-occurring 
disorders, prior treatment experiences, and patient preference.  
 Medication side-effect profile. For depression characterized by low energy, one of the 
more activating agents like SSRIs, SNRIs, and bupropion may be preferred. If sexual side effects 
are a concern for the patient, then bupropion can be used. If the patient has a history of seizures 
or an eating disorder, then bupropion is contraindicated since it can lower the seizure threshold. 
Trazodone is a good choice for depression characterized by insomnia (Thaler et al., 2012), and 
mirtazapine’s side effect of weight gain can be utilized for those with a loss of appetite (Uguz, 
Sahingoz, Gungor, Aksoy, & Askin, 2015).  
 Patient demographics. Many studies have looked at whether patient demographics, such 
as age, gender, race, and socioeconomic status affect antidepressant efficacy.  
 Age. Studies that explored the association between age and drug efficacy used a range of 
minimum ages to define older age, with age cutoffs ranging from 50 to 70 years old. These 
studies found that nonresponse to antidepressant medication in general is more likely in older 
patients (Sherbourne, Schoenbaum, Wells, & Croghan, 2004). However, there is no difference in 
efficacies between various second-generation antidepressants in this population (Gartlehner et al., 
2011). Thus, physicians can expect a poorer response to medication in older patients, but older 
age cannot be used as the basis of recommending a specific medication. In pediatric patients, 
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however, fluoxetine can be recommended because it is the only antidepressant approved for 
treating depression in children ages eight and older (March et al., 2004). 
 Gender. Potential reasons for sexual differences in antidepressant response include 
differences between males and females with respect to hormone levels, drug metabolism, and 
behavioral characteristics (Sramek, Murphy, & Cutler, 2016; Yonkers, Kando, Cole, & 
Blumenthal, 1992). Estrogen and progesterone have been theorized to be implicated in the 
pathogenesis of depression. This is supported by the observation that differences in the 
prevalence of MDD between males and females do not emerge until puberty (Faravelli, Scarpato, 
Castellini, & Lo Sauro, 2013) and disappear after menopause (Bebbington et al., 2003). Estrogen 
and progesterone have also been shown to decrease gastric motility, which affects the clearance 
of antidepressants (Young et al., 2009; Hutson, Roehrkasse, & Wald, 1989). In addition, females 
have a higher percentage of body fat than men (Blaak, 2001), which can affect metabolism of 
lipophilic antidepressant medications.  
While there is a theoretical basis for differences in antidepressant response between 
males and females, studies looking at this effect have had mixed results. In many studies, 
females have been shown to respond better than males to serotonergic agents (Kornstein et al., 
2000; Naito et al., 2007; Young et al., 2009). In addition, a few studies have shown males 
respond better than females to TCAs and MAOIs (Kornstein et al., 2000; Frank, Carpenter, & 
Kupfer, 1988), and one study found females responded better to MAOIs than males (Quitkin et 
al., 2002). However, there have also been many studies that found no significant difference 
between males and females in the response to SSRIs, MAOIs, or TCAs (Entsuah, Huang, & 
Thase, 2001; Quitkin et al., 2002; Parker, Parker, Austin, Mitchell, & Brotchie, 2003; Wohlfarth 
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et al., 2004; Pinto-Meza, Usall, Serrano-Blanco, Suarez, & Haro, 2006; Kornstein et al., 2014; 
Cuijpers et al., 2014). 
 In terms of adverse effects, a meta-analysis of 234 RCTs found one trial in which men 
were reported to have a higher risk of sexual dysfunction than women when taking paroxetine, 
and another trial in which women were reported to have greater sexual dysfunction when taking 
paroxetine compared to sertraline (Gartlehner et al., 2011). 
 Pregnancy. Paroxetine and nortriptyline should be avoided in pregnancy since they are in 
the Food and Drug Administration (FDA) Pregnancy Category D (i.e., there is positive evidence 
of human fetal risk based on adverse reaction data or studies in humans) (Lin & Stevens, 2014). 
Most other antidepressants are Category C (i.e., there are no adequate or well-controlled studies 
in humans) and should be used with caution (Lin & Stevens, 2014). 
Race. A meta-analysis of 234 RCTs found there were no head-to-head trials or studies 
directly comparing differences in efficacy between groups identified by race or ethnicity 
(Gartlehner et al., 2011). Thus, physicians cannot choose an antidepressant based on race using 
the present data. 
 Socioeconomic status. Unemployment has been shown to be a predictor of nonresponse 
to antidepressants in patients with depression (Sherbourne et al., 2004). This suggests that 
physicians can expect a poorer response to antidepressants in general for patients of a lower 
socioeconomic status. However, socioeconomic status cannot be used as the basis for predicting 
which specific antidepressant will be most efficacious in these patients.  
While socioeconomic status cannot help physicians choose an antidepressant based on 
efficacy, it can help physicians choose an antidepressant based on cost. For patients in which 
cost is a barrier to treatment, citalopram, fluoxetine, and sertraline are relatively low-cost SSRIs. 
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In contrast, escitalopram, fluvoxamine, and milnacipran, are more expensive SSRIs. Low-cost 
atypical antidepressant options include mirtazapine, and trazodone (Lin & Stevens, 2014). 
 Clinical presentation. Since depression is a heterogenous disease and can present in 
many ways, most psychiatrists pick antidepressant medications for their patients based on 
symptom clusters within the clinical presentation (Zimmerman et al., 2004). Common symptom 
clusters upon which psychiatrists base their antidepressant choices are anxiety, sleep, fatigue, 
and pain (Zimmerman et al., 2004; Lin & Stevens, 2014; Thaler et al., 2012). Based on this 
method, psychiatrists would choose a sedating drug for those with anxiety or insomnia, an 
activating drug for those with fatigue, and an SNRI for those with neuropathic pain. While the 
choices psychiatrists make are theoretically logical from a neurobiological point of view, 
empirical evidence has been sparse and inconclusive. Choosing antidepressants based on the 
predominant clinical presentation of depression has been shown to improve treatment outcomes 
in many trials (Fava et al., 1997; Kornstein & Schneider, 2001), but a few trials have found that 
there is no superior antidepressant for any specific symptom cluster (Thaler et al., 2012; Gaynes 
et al., 2011). These trials, however, were often underpowered.  
 Anxiety. Since anxiety is regulated by serotonergic neurons in the limbic system, SSRIs 
should theoretically be the optimal treatment in anxiety-predominant depression (Lin & Stevens, 
2014). This is supported by the fact that most SSRIs are also FDA approved to treat generalized 
anxiety disorder, panic disorder, and obsessive-compulsive disorder (Lin & Stevens, 2014). 
Since norepinephrine is associated with the sympathetic fight or flight response, drugs that 
increase norepinephrine, such as SNRIs and bupropion, should theoretically be avoided in this 
population due to their potential to provoke anxiety (Lin & Stevens, 2014). While this makes 
theoretical sense, a systematic review of RCTs found that treatment efficacy did not differ 
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between antidepressant medications in treating anxiety associated with depression (Thaler et al., 
2012).  
Insomnia. Sleep is regulated by 5HT2a receptors in the brainstem (Thase, 1999). Thus, 
antidepressants that block 5HT2A receptors, such as mirtazapine and trazodone, should be 
optimal treatments in insomnia-predominant depression. In fact, studies have shown that 
mirtazapine shortens sleep onset time and increases sleep duration (Thase, 1999). Trazodone and 
mirtazapine are common drugs chosen by psychiatrists in treating depression with insomnia (Lin 
& Stevens, 2014). Like anxiety-predominant depression, drugs with norepinephrine activity, 
such as SNRIs and bupropion, should be avoided in insomnia-predominant depression due to 
their activating effects.  
 While a 2012 systematic review found fluoxetine and mirtazapine to be equally effective 
at treating depression with insomnia, trazodone was found to be significantly better at improving 
sleep disturbance when compared to both fluoxetine and venlafaxine (Thaler et al., 2012). 
 Fatigue. Fatigue-predominant depression often comes clustered with decreases in energy, 
attention, and concentration. These symptoms are regulated by a decrease in dopamine and 
norepinephrine (Lin & Stevens, 2014). In fact, psychiatrists most commonly prescribe SNRIs, 
bupropion, and fluoxetine (an SSRI with some norepinephrine activity) to treat depression with 
fatigue (Lin & Stevens, 2014). Sedating drugs, such as trazodone and mirtazapine, should be 
avoided in these patients.  
 Analysis of the data from the ‘Sequenced Treatment Alternatives to Relieve Depression’ 
(STAR*D) trial found that augmentation with bupropion was more likely than buspirone to 
produce remission in patients with depression characterized by low energy. However, switching 
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to venlafaxine, an SNRI, or bupropion was less likely to produce remission than switching to 
sertraline, an SSRI (Gaynes et al., 2011).  
 Pain. Pain is thought to be mediated by decreases in serotonin and norepinephrine, which 
affects the endogenous opioid system (Ozdemir, Gursoy, & Bagcivan, 2012). Thus, SNRIs 
should theoretically be optimal in depression with pain. In fact, many SNRIs are FDA approved 
to treat both depression and neuropathic pain, such as pain from fibromyalgia or diabetic 
neuropathy (Lin & Stevens, 2014). 
 The costs, indications, and potential side effects of second-generation antidepressants are 
summarized in Table 1. 
Table 1 
 
Second-Generation Antidepressants 
 Fluoxetine Sertraline Citalopram Paroxetine Venlafaxine Bupropion Trazodone 
Cost1 $ $ $ $ $$ $$ $ 
Pregnancy Category2 C C C D C C C 
Other Indications - - - - Neuropathic Pain 
Weight Loss, 
Smoking 
Cessation 
Insomnia 
Contraindications - - - - - Seizures, Eating disorders - 
Side Effects        
N/V Yes Yes Yes Yes Yes Yes No 
Diarrhea/Constipation Yes Yes Yes Yes Yes No No 
Decreased Libido Yes Yes Yes Yes Yes No Yes 
HTN No No No No Yes Yes No 
Dry Mouth No No No No Yes Yes No 
Serotonin Syndrome Yes Yes Yes Yes Yes No Yes 
Priapism No No No No No No Yes 
Anxiety  Yes Yes Yes Yes Yes Yes No 
Fatigue  No No No No No No Yes 
Weight Increase Increase Increase Increase - Decrease - 
1$= less than $50 per month; $$= $50-$100/month 
2C= there are no adequate or well-controlled studies in humans; D=There is positive evidence of human fetal risk based on 
adverse reaction data or human studies 
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Choosing an Antidepressant based on Genomic and Imaging Data 
 Despite using medication side effect profiles, patient demographics, and clinical 
presentation to guide the selection of antidepressants, less than 50% of patients respond to their 
first antidepressant, and many patients must try multiple drugs before finding one that works 
(Singh et al., 2017; Aldi, Baethge, Heinz, Langlitz, & Bauer, 2005). Thus, researchers have 
attempted to help guide physicians in their choice of antidepressants by utilizing genomic data 
and imaging data. 
 Genomic data. Although gene expression analysis is difficult to do in MDD because 
brain tissue is relatively inaccessible, single nucleotide polymorphisms (SNPs) of various genes 
can be obtained from any tissue in the body. Multiple SNPs have been studied for their 
association with antidepressant treatment response, and many companies are now advertising 
proprietary algorithms that use a patient’s DNA sample to guide the choice of antidepressants 
(Rosenblat, Lee, & McIntyre, 2018). 
 ABCB1. The ABCB1 gene codes for p-glycoprotein, a protein involved in the transport of 
compounds out of the blood brain barrier. Thus, this gene can theoretically affect drug 
concentration levels at the brain, making it a promising target in studying antidepressant efficacy. 
In 2015, Schatzberg et al. looked at 10 different SNPs in 683 patients and found that functional 
polymorphisms in rs1024583 differentially affected response to antidepressants. Those 
homozygous for the T allele had increased activity of p-glycoprotein and a poorer response to 
escitalopram and sertraline. This could be because the overactive p-glycoprotein is transporting 
the drug out of the cerebrospinal fluid, decreasing the levels of the drug at the brain. However, 
those homozygous for the T allele also had a significantly better response to venlafaxine, a result 
the researchers could not explain. Efficacy to these three drugs was also inversely correlated with 
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side effect levels. These results are consistent with many other studies (Uhr et al., 2008; Lin et al., 
2011; Singh, Bousman, Ng, Byron, & Berk, 2012) while others have had inconsistent results 
(Perlis, Fijal, Dharia, Heinloth, & Houston, 2010). 
5HTTLPR and 5HT2a. Polymorphisms in the serotonin transporter 5HTTLPR and the 
serotonin postsynaptic receptor 5HT2a have been studied with relation to SSRI efficacy. Again, 
study results have been mixed (Anguelova, Benkelfat, & Turecki, 2003). McMahon et al. (2006) 
found polymorphisms in these genes to be correlated with treatment response to citalopram, 
while Leuchter et al. (2009) found that these polymorphisms were not significant predictors of 
treatment response to escitalopram or bupropion. 
 UBE3C. A third gene that shows promise in predicting antidepressant response is 
UBE3C, which encodes for the ubiquitin protein ligase E3C (Leuchter et al., 2010). This gene 
has been shown to be significantly downregulated in a stress-induced manner in the ventromedial 
prefrontal cortex and has been associated with escitalopram and nortriptyline treatment response. 
 Brain structure and function. Measures of brain structure and function, such as 
quantitative electroencephalogram (QEEG) and magnetic resonance imaging (MRI) scans, have 
been studied in their ability to predict response to antidepressant treatment.  
 QEEG. Currently, the best-documented brain functional biomarker in predicting 
antidepressant response is QEEG (Leuchter et al., 2009; Leuchter et al., 2010; Koenig, Studer, 
Hubl, Melie, & Strik, 2005). In particular, the Antidepressant Treatment Response Index (ATR), 
a type of QEEG, has been shown to significantly predict remission of depressive symptoms with 
escitalopram (Leuchter et al., 2009).  
 MRI. There are two common ways that MRIs are utilized in predicting antidepressant 
response: intrinsic connectivity analysis and task-related analyses. In intrinsic connectivity 
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analyses, the patient lays in the scanner with their eyes closed, allowing researchers to obtain a 
picture of brain anatomy. In task-related analyses, a functional MRI (fMRI) is utilized. Typically, 
subjects lay in the machine with their eyes open, and researchers measure levels of activity in 
different areas of the brain while the subject views negative emotional facial expressions.  
Intrinsic connectivity analysis. Intrinsic connectivity analyses have found that patients 
with depression have decreased corticolimbic connectivity (Anand et al., 2005) and reduced gray 
matter in the anterior cingulate cortex (Koolschjn, van Haren, Lensvelt-Mulders, Hulshoff Pol, & 
Kahn, 2009), subgenual cingulate cortex (Hajek, Kozeny, Kopecek, Alda, & Hoschl, 2008), and 
the hippocampus (McKinnon, Yucel, Nazarov, & MacQueen, 2009). Changes in the 
hippocampus may be useful in predicting antidepressant treatment response: larger hippocampi 
are associated with better responses to antidepressants while smaller hippocampi are associated 
with poorer responses to antidepressants. This result has been obtained in citalopram, 
venlafaxine, bupropion, mirtazapine, sertraline, fluoxetine, and fluvoxamine (MacQueen, Yucel, 
Taylor, Macdonald, & Joffe, 2008; Vakili et al., 2000; Frodl et al., 2008). In addition, levels of 
cerebral metabolism, white-matter lesions, and levels of brain atrophy pretreatment may be 
useful predictors of treatment outcome (Leuchter et al., 2009). However, other studies have 
shown that structural MRI imaging does not seem to be a useful predictor of antidepressant 
response (Schmaal et al., 2015). 
Task-related analysis. Task-related analyses have found increased activity in the 
amygdala in depressed patients while looking at negative emotional facial expressions 
(Surguladze et al., 2005). Fu et al. (2008) used this information along with machine learning 
techniques to create an algorithm that could differentiate two different groups: 1) patients with 
depression from patients without depression, and 2) whether a patient with depression will 
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respond to treatment. This algorithm was able to correctly distinguish between patients with 
depression and patients without depression with an 84% sensitivity and 89% specificity. While 
the sample size was too small to significantly differentiate patients who will respond to treatment 
from those who will not, the data showed a trend toward significance.  
Another study found decreased connections between the amygdala and anterior cingulate, 
and eight weeks of fluoxetine administration increased these connections between the amygdala 
and anterior cingulate (Chen et al., 2008). 
Choosing an Antidepressant by Combining Multiple Variables  
 Rather than looking at the impact of individual factors (e.g., demographic, genomic 
information, brain imaging, etc.) that each have a minimal ability to predict treatment response, it 
may be beneficial to simultaneously use multiple variables to predict an individual’s response to 
treatment. These variables may have additive effects, increasing our ability to accurately predict 
treatment response. Machine learning is one such way of simultaneously utilizing many variables 
to empirically predict antidepressant response. A literature review found only one study that has 
used machine learning to predict antidepressant treatment response (Chekroud et al., 2016). This 
study used the STAR*D trial data to develop an algorithm to assess whether patients will achieve 
remission of depression following a 12-week course of citalopram. This algorithm used 25 
predictive variables and was able to predict outcomes within the STAR*D cohort with 64.6% 
accuracy (p < .0001). This model was then externally validated with the escitalopram treatment 
group of the ‘Combining Medications to Enhance Depression Outcomes’ (COMED) trial with an 
accuracy of 59.6% (p < .0001). Although demographic information, clinical presentation, 
symptom clustering, imaging, and genomic data each provide minimal information on which 
patients might respond best to which drug, combining all these factors together into a single 
CHOOSING A SECOND-GENERATION ANTIDEPRESSANT 23 
algorithm seems to have an additive effect. Chekroud et al. (2016) found significant results by 
doing this with citalopram, and if this same process were repeated for all commonly used first-
line antidepressants, clinicians would be equipped with empirical evidence to confidently 
prescribe a specific drug to a specific patient. 
Methods 
 This study utilized a secondary analysis of data from the Collaborative Psychiatric 
Epidemiology Surveys (CPES), a pre-existing, de-identified data set. Demographic 
characteristics, clinical symptoms, past medical history, current medications and treatments, and 
compliance were extracted from participants who had reported using one of the seven drugs of 
interest (i.e., citalopram, fluoxetine, paroxetine, sertraline, venlafaxine, bupropion, and trazadone) 
within the past year. Chi-square analyses were then conducted to screen for variables 
significantly associated with the efficacy of each drug. Variables that were significantly 
associated with drug efficacy (p < .05) were included in all subsequent analyses.  
 In the first set of analyses, clinical symptoms were grouped into five symptom clusters 
(i.e., mood, anxiety, fatigue, insomnia, and appetite) and included in a multivariable logistic 
regression to look for associations between symptom clusters and a drug’s efficacy in treating 
sadness. Demographics, past medical history, current medications and treatments, and 
compliance were controlled for by using a principal component analysis (PCA) with the resulting 
PCs included as independent variables in the logistic regression.  
In the second set of analyses, fifty percent of the subjects were removed from the 
analyses to form a testing cohort. The remaining 50% constituted the training cohort. A PCA that 
included all clinical symptoms, demographics, past medical history, current medications and 
treatments, and compliance was run on the training cohort, and the resulting PCs were included 
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in a regression analysis to create models that predict each drug’s efficacy in treating sadness. 
Accuracy and internal validity of the models were tested using the training cohort and the testing 
cohort, respectively.   
This study is exempt from Institutional Review Board (IRB) evaluation, per 45 Code of 
Federal Regulations (CFR) part 46 of the Human Subjects Regulations Decision Chart 1 (see 
Appendix A). 
Study Sample 
Data from the CPES (N = 20,013) was obtained through the Inter-university Consortium 
for Political and Social Research (ICPSR). The CPES includes data collected from 2001 to 2003 
and is a combination of three separate surveys all administered by trained lay interviewers: the 
National Comorbidity Survey Replication (NCS-R) (n = 9,282), the National Survey of 
American Life (NSAL) (n = 6,082), and the National Latino and Asian American Study 
(NLAAS) (n = 4,649). All subjects were adults living in households within the United States. 
Institutionalized adults and people living on a military base were excluded from this sample. In 
addition, the NCS-R and NSAL excluded non-English speakers. The CPES used a multi-stage 
probability sampling design to create a representative sample of the total United States 
population, as well as special populations including Asian and Latino adults. The average 
response rate for the CPES was 72.1%. Further details of the methodology of the CPES are 
provided elsewhere (Pennel et al., 2004). 
A subsample of participants who had taken one of the seven drugs of interest was 
included in this study. Participants were asked whether they had taken a prescription medication 
for ‘emotions, nerves, mental health, substance use, energy, concentration, sleep, or ability to 
cope with stress’ within the past year. Those who endorsed this statement were asked to select 
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the name of the medication they had taken, and each participant could choose up to 20 
medications. Because subsequent questions about compliance, reason for taking the medication, 
and effectiveness were only asked about the first three medications the participants selected, our 
analysis was limited to the first three medications participants cited. Any participant who listed 
fluoxetine (n = 217), sertraline (n = 330), citalopram (n = 139), paroxetine (n = 283), venlafaxine 
(n = 99), bupropion (n = 154), or trazadone (n = 105) as one of their first three medications were 
included in this study (n = 1,162). Eighty-nine percent of the mentions of any of these seven 
medications were captured within the first three mentions. 
Outcome Measures 
In the CPES survey, participants were asked to list the reasons for which they were taking 
the medication (e.g., sadness, sleep, concentration, etc.) for each of their first three medication 
mentions. This study included all participants who were taking their medication to treat sadness. 
Then, participants were asked, “Overall, how effective was [medication name] in doing the 
things you expected it to do – very, somewhat, not very, or not at all effective?” In this study, 
answers of “very effective” were coded as effective, while “somewhat effective,” “not very 
effective,” and “not at all effective” were coded as ineffective. 
Covariates 
Demographic characteristics. Age, sex, body-mass index (BMI), race-ethnicity, marital 
status, educational attainment, insurance status, employment status, and income to needs ratio 
were included in the analyses. 
 Substance use. Smoking status, alcohol consumption, illegal uses of prescription drugs, 
marijuana use, and cocaine use were included in the analyses. For each substance, participants 
were asked the question, “Did you use [substance] at any time within the past 12 months?” 
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Options included “yes,” “no,” “don’t know,” and “refused to answer.” Alcohol consumption 
included both the frequency at which the participant typically drinks alcohol as well as the 
quantity of alcohol consumed during each occurrence over the past year.  
Overall health status. Participants were asked to rate their overall mental health and 
overall physical health. Options included “excellent,” “very good,” “good,” “fair,” and “poor.” 
To assess overall functional status, participants were asked whether they had been “limited in 
any way for the past three months because of any impairment or health problems.” Participants 
who responded with a “yes,” were subsequently asked how long this impairment lasted. 
Diagnoses. Psychiatric diagnoses were based on the WHO World Mental Health 
Composite International Diagnostic Interview (WMH-CIDI) using Diagnostic and Statistical 
Manual of Mental Disorders IV (DSM-IV) diagnostic codes. Diagnoses made in this manner are 
comparable to those made by clinicians (Kessler & Ustun, 2004; Kessler et al., 2005).  
For physical diagnoses, participants were given a list of 20 different possible chronic, 
physical diagnoses and were told to choose all that apply. This list is a modified checklist from 
the National Health Interview Survey.  
 Symptoms. Symptom type and severity were derived from the Kessler Psychological 
Distress Scale (K10), a ten-question screening tool that measures symptoms associated with 
anxiety and depression (Kessler et al., 2002). For this scale, participants were asked to think 
about “the one month in the past 12 months when you were at your worst emotionally in terms of 
being anxious, depressed, or emotionally stressed. If there was no month like this, think of a 
typical month in the past 12 months.”  
While the K10 asked about symptoms present within the past year, three additional 
questions in the screening section of the CPES questionnaire asked about present symptoms. 
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These three questions from the screening questionnaire were included to provide additional 
information about current sleep, appetite, and anxiety. For sleep, participants were asked, “How 
often do you have trouble getting to sleep or staying asleep?” For appetite, they were asked, 
“How often do you have loss of appetite?” For anxiety, they were asked, “How often have you 
been bothered by nervousness, feeling fidgety, or tense?” For each of these questions, 
participants have the option of choosing “nearly all the time,” “pretty often,” “not very much,” or 
“never.” 
Medications.  
 Categorization. If a medication mentioned was not one of the seven medications of 
interest, it was classified into a group based on drug class. Twelve drug groups were used: 
stimulants, anti-psychotics, benzodiazepines, non-benzodiazepine hypnotics (NBH), 
antihistamines, barbiturates, mood stabilizers, anticholinergic, anti-convulsant, alpha agonist, 
other anxiolytic, and other non-anxiolytic. Medications that are a mix of two different 
medications were coded as being in both medications’ drug classes (e.g., Etrafon, which is a 
combination of amitriptyline and perphenazine, was coded as both a TCA and an antipsychotic 
medication). 
Noncompliance. To assess medication compliance, participants were asked, ‘‘How many 
days out of 30 did you typically either forget to take it or take less of it than you were supposed 
to?’’ Although there is no consensus on the threshold that should be used to define non-
compliance, previous studies have used compliance rates between 80% and 95% (Faravelli et al., 
2013). This study defined strict compliance as taking the medication at least 90% of the time, 
and liberal compliance was defined as taking the medication at least 80% of the time (Jeon-
Slaughter, 2012). Thus, those who missed their medication more than three days per month were 
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considered noncompliant using the strict definition and those who missed their medication more 
than six times per month were considered noncompliant using the liberal definition. 
Other treatments. To understand the kinds of treatment each participant had tried in 
conjunction with their medications, we included three variables: 1) whether the participant had 
ever had a therapy session for >30 minutes, 2) whether the participant had ever been hospitalized 
for problems with their nerves, mental health, or use of alcohol or drugs, and 3) whether the 
participant had used any alternative therapies in the past year. Examples of alternative therapies 
provided to the participant were acupuncture, biofeedback, chiropractic, energy healing, exercise 
or movement therapy, herbal therapy, high dose megavitamins, homeopathy, hypnosis, imagery 
techniques, massage therapy, prayer or other spiritual practices, relaxation or meditation 
techniques, special diets, spiritual healing by others, and any other non-traditional remedies or 
therapies. 
Statistical Analysis 
 SPSS version 25 was used to conduct statistical analyses. Descriptive analyses were 
performed on all 97 covariates for each of the seven drug groups. This included nine 
demographic characteristics, four variables on health status, 27 lifetime mental health diagnoses, 
13 depression symptoms, six variables on treatments and substances, 24 possible current 
medications, and 14 variables on compliance (see Table 2).  
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 To screen for variables, individual chi-square analyses were performed for every 
combination between the 97 variables studied and the efficacy of the seven drugs. All variables 
significantly associated with drug efficacy (p < .05) were included in two separate, subsequent 
analyses: one to find associations between symptom clusters and drug efficacy, and another to 
create a model that predicts drug efficacy. 
Symptom cluster associations. Following the chi-square analyses, variables associated 
with symptom types (i.e., questions from the K10 and screening surveys) were standardized on a 
scale ranging from zero to one. People with a value of zero experienced the symptom none of the 
time while those with a value of one experienced the symptom all the time. Symptoms associated 
with decreased mood were summed to create a total mood score, and this process was repeated to 
create an anxiety score, fatigue score, insomnia score, and appetite score. The symptoms that 
make up each score are shown in Table 3. 
Table 3 
Survey Questions Included in Each Score 
Mood Score Anxiety Score Fatigue Score Insomnia Score Appetite Score 
K10 Survey K10 Survey K10 Survey Screening Survey Screening Survey 
Hopelessness Nervousness Tired Insomnia Decreased appetite 
Worthlessness Nothing calmed you Everything was an effort 
 
  
Depressed Fidgety 
  
  
Nothing cheered you up Couldn't sit still 
  
  
  Screening Survey 
  
  
  Anxiety         
 
A PCA was conducted using the variables that screened positive on the chi-square 
analyses. This PCA did not include clinical symptoms. A regression method was used to 
calculate factor scores, and components with an Eigenvalue ≥ 1 were included in subsequent 
analyses.  
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The resulting principal components were included in a multivariable logistic regression 
analysis. The dependent variables were the principal components and relevant symptom scores. 
The independent variable was the drug’s efficacy in treating sadness. 
Model creation. In a separate analysis, 50% of the participants were removed from the 
data to form the testing cohort. The remaining 50% of participants constituted the training cohort. 
For each of the seven drugs, a separate PCA was performed using the variables that screened 
positive on the chi-square tests. This time, the clinical symptoms were included. A regression 
method was used to calculate factor scores, and components with an Eigenvalue ≥ 1 were 
included in subsequent analyses. 
A multivariable logistic regression was performed on the training cohort using principal 
components as the independent variables and effectiveness of the drug in treating sadness as the 
dependent variable. These models were then applied to the testing cohort to assess their validity. 
Methods for the statistical analysis are summarized in Figure 1. 
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Results 
Descriptive Analysis 
In total, 1,162 participants took one of the seven drugs of interest within the past 12 
months. Within the past 12 months, 85.97% of people took only one of the seven medications, 
13.16% took two of the seven medications, and 0.86% took three of the seven medications. The 
subsample of participants who took fluoxetine, sertraline, citalopram, paroxetine, venlafaxine, 
bupropion, and trazodone represent 2,374,066.524 (SE= 304,321.115), 2,872,686.689 (SE= 
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213,522.755), 1,333,959.677 (SE=251,037.292), 2,179,510.792 (SE=253,542.893), 
1,004,892.689 (SE=120,447.118), 1,345,820.685 (SE=163,977.012), and 402,731.505 
(SE=56,266.937) of the total United States population, respectively. The percentage of people 
who found fluoxetine, sertraline, citalopram, paroxetine, venlafaxine, bupropion, and trazodone 
to be effective were 52.8%, 59.3%, 40.8%, 51.9%, 58.9%, 46.3%, and 72.0%, respectively (see 
Figure 2).  
 
Figure 2. Effectiveness of each drug 
In each of the seven groups, there were more than twice as many women as men, more 
than three quarters of participants were privately insured, and more than 80% identified as non-
Latino white. Mean age of these seven groups ranged from 42.3 to 49.7, and mean income to 
needs ratio ranged from 3.90 to 4.87 (see Table 4). 
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Table 4 
Demographic Characteristics 
 Fluoxetine (%) 
Sertraline 
(%) 
Citalopra
m (%) 
Paroxetin
e (%) 
Venlafaxine 
(%) 
Bupropion 
(%) 
Trazodone 
(%) 
Sex 
     Male 
     Female 
 
24.9 
75.1 
 
24.9 
75.1 
 
30.1 
69.9 
 
29.3 
70.7 
 
29.7 
70.3 
 
30.7 
69.3 
 
21.4 
78.6 
Mean Age (sd) 45.9 (14.8) 45.3 (15.2) 44.8 (15.1) 45.1 (15.6) 43.5 (12.9) 42.3 (12.4) 49.7 (13.2) 
BMI 
     <25 
     ≥25 
 
36.2 
63.8 
 
39.8 
60.2 
 
41.6 
58.4 
 
43.5 
56.5 
 
26.8 
73.2 
 
48.0 
52.0 
 
33.6 
66.4 
Race-Ethnicity 
     Non-Latino  
          White 
     African  
          American 
     Hispanic 
     Asian 
     Other 
 
88.6 
 
2.6 
 
5.3 
0.5 
2.9 
 
81.1 
 
6.9 
 
9.4 
1.1 
1.5 
 
85.6 
 
3.8 
 
6.8 
0.5 
3.3 
 
82.2 
 
5.2 
 
6.6 
2.1 
3.9 
 
87.9 
 
3.2 
 
7.6 
1.2 
0.1 
 
90.0 
 
2.6 
 
5.1 
1.0 
1.2 
 
86.7 
 
4.4 
 
5.5 
0.7 
2.6 
Marital Status 
     Married or 
          cohabiting 
     Divorced,  
          separated,  
          or widowed 
     Never married 
 
49.2 
 
30.8 
 
 
20.0 
 
54.7 
 
27.9 
 
 
17.4 
 
58.6 
 
21.2 
 
 
20.2 
 
52.7 
 
23.5 
 
 
23.7 
 
44.5 
 
31.2 
 
 
24.4 
 
57.1 
 
21.3 
 
 
21.6 
 
65.6 
 
24.8 
 
 
9.6 
High School 
Diploma 
     No 
     Yes 
 
16.0 
84.0 
 
16.3 
83.7 
 
13.0 
87.0 
 
18.3 
81.7 
 
12.3 
87.7 
 
8.5 
91.5 
 
11.1 
88.9 
Insurance  
     Private 
     Public 
     Other 
 
75.6 
23.3 
1.1 
 
75.7 
21.7 
2.6 
 
80.5 
17.5 
2.0 
 
78.8 
20.8 
0.4 
 
79.2 
19.3 
1.4 
 
79.0 
14.4 
6.6 
 
82.7 
17.2 
0.1 
Employment 
     Employed 
     Unemployed 
 
41.9 
58.1 
 
42.5 
57.5 
 
39.9 
60.1 
 
50.9 
49.1 
 
33.9 
66.1 
 
40.9 
59.1 
 
53.2 
46.8 
Mean Income to  
   Needs Ratio (sd) 
 
4.03 (3.84) 
 
4.02 (3.98) 
 
4.20 (3.44) 
 
3.90 (3.56) 
 
4.48 (4.04) 
 
4.87 (4.23) 
 
3.91 (3.77) 
sd= standard deviation 
 
Chi-square Analysis 
 Chi-square tests found 15, 21, 13, 16, 9, and 16 of the 97 variables to be correlated with 
the effectiveness of fluoxetine, sertraline, citalopram, paroxetine, venlafaxine, bupropion, and 
trazodone, respectively (p < .05) (see Table 5).
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Symptom Cluster Associations 
The logistic regression analysis found that when controlling for demographics, past 
medical history, current mental health treatments and medications, and medication compliance, 
an increase in the anxiety score led to significantly increased odds that fluoxetine would be 
ineffective at treating sadness, an increase in the fatigue score led to significantly increased odds 
that sertraline would be ineffective at treating sadness, an increase in the mood score led to 
significantly increased odds that paroxetine and venlafaxine would be ineffective at treating 
sadness (see Table 6). The efficacy of bupropion in treating sadness was not associated with the 
presence or severity of any clinical symptoms. Regression results for trazodone were excluded 
due to a small sample size. 
Table 6 
Multivariable Logistic Regression Results 
    95% Confidence Interval  
  OR Lower Upper p-value 
Fluoxetine 
   
 
Mood Score 2.117 0.994 4.507 0.052 
Anxiety Score 4.014 1.527 10.554 0.007 
Fatigue Score 1.893 0.232 15.442 0.531 
Appetite Score 1.138 0.171 7.557 0.887 
Sertraline     
Mood Score 0.514 0.164 1.606 0.238 
Fatigue Score 30.957 1.914 500.723 0.018 
Insomnia Score 0.944 0.166 5.382 0.946 
Appetite Score 7.102 0.904 55.766 0.061 
Citalopram     
Mood Score 1.733 0.849 3.540 0.111 
Appetite Score 0.256 0.037 1.781 0.141 
Paroxetine     
Mood Score 2.831 1.017 7.879 0.047 
Anxiety Score 2.021 0.286 14.296 0.057 
Fatigue Score 0.891 0.336 2.362 0.804 
Venlafaxine     
Mood Score 1.876 1.041 3.379 0.039 
Insomnia Score 2.463 0.522 11.621 0.212 
Appetite Score 2.435 0.400 14.841 0.282 
OR=Odds Ratio 
Statistically significant values are bolded. 
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Model Creation 
Principal component analysis. Fluoxetine, sertraline, citalopram, paroxetine, 
venlafaxine, bupropion, and trazodone had eight, six, seven, four, six, five, and five principal 
components (PCs), respectively (see Tables 7a-7g).  
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Table 7a 
Principal Component Loadings for Fluoxetine 
  PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 
Demographics 
        Sex 0.020 0.457 0.148 0.158 0.181 0.149 -0.373 -0.571 
Lifetime MH Dx         
Bipolar 2 -0.398 0.403 -0.438 0.095 -0.366 -0.167 -0.258 0.237 
Bipolar Subthreshold 0.153 -0.092 -0.312 0.242 -0.225 0.482 0.599 -0.012 
PA -0.401 0.292 -0.221 0.002 0.187 0.304 0.095 0.078 
Adult Separation Anxiety -0.046 0.356 0.282 -0.363 -0.023 0.627 -0.136 0.092 
Agoraphobia without PA -0.499 0.489 -0.219 0.332 0.094 0.073 -0.187 0.388 
Binge Eating -0.023 0.276 0.627 0.332 -0.369 0.144 -0.061 0.162 
Bulimia -0.063 0.091 0.656 0.340 -0.354 -0.163 0.229 0.013 
Txt and Substances         
Ever Hospitalized -0.084 0.158 0.095 -0.719 0.046 0.105 0.223 0.096 
K10 Survey         
Hopeless 0.793 0.123 -0.113 -0.081 0.010 0.133 -0.070 -0.008 
Fidgety 0.628 -0.086 0.016 -0.047 0.146 0.046 -0.179 0.321 
Worthless 0.745 0.276 -0.214 -0.177 -0.148 -0.108 -0.049 -0.191 
Nothing calmed you 0.631 0.053 0.106 0.379 0.312 0.277 -0.073 -0.163 
Depressed 0.601 0.503 -0.186 0.040 -0.271 0.108 0.179 0.080 
Nothing cheered you up 0.584 0.493 -0.168 0.132 -0.075 -0.310 0.120 0.022 
Everything was an effort 0.652 0.256 0.164 -0.087 0.273 -0.277 0.054 0.201 
Screening Survey         
Anxiety 0.520 -0.306 0.272 -0.050 0.160 0.064 -0.122 0.449 
Appetite 0.365 -0.398 -0.194 0.433 0.049 0.066 0.093 -0.004 
Medications         
Total # meds -0.209 0.480 0.236 -0.155 0.285 -0.262 0.439 -0.102 
Citalopram -0.315 0.213 -0.007 0.338 0.697 -0.008 0.183 0.144 
The variables with the largest loadings into each of the principal components are shown in bold. 
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Table 7b 
 
Principal Component Loadings for Sertraline 
 
 
PC1 PC2 PC3 PC4 PC5 PC6 
Demographics       
Age 0.267 -0.579 0.145 0.265 -0.098 -0.081 
Income to Needs 0.445 -0.088 0.255 -0.104 0.000 0.220 
Marital status -0.378 0.530 -0.441 0.221 -0.058 -0.146 
Lifetime MH Dx       
Bipolar Subthreshold -0.160 0.178 0.775 -0.036 0.200 0.169 
Hypomania 0.030 0.217 -0.287 0.659 0.366 0.269 
GAD -0.088 0.268 0.402 0.459 -0.107 0.427 
ODD -0.239 0.634 0.109 -0.141 -0.179 -0.245 
K10 Survey       
Hopeless 0.663 0.011 0.004 0.038 0.428 -0.175 
Worthless 0.789 0.152 0.015 0.119 0.251 -0.145 
Depressed 0.766 0.025 -0.038 0.078 -0.100 -0.206 
Everything was an effort 0.752 0.333 -0.068 -0.030 -0.130 -0.068 
Screening Survey       
Insomnia 0.518 0.236 0.045 -0.183 -0.323 0.267 
Appetite 0.309 0.420 0.044 -0.248 0.006 0.195 
Medications       
Fluoxetine -0.128 0.024 -0.277 -0.500 0.562 0.350 
Sertraline Strict Comp 0.289 -0.189 -0.456 -0.029 -0.336 0.526 
 
The variables with the largest loadings into each of the principal components are shown in bold. 
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Table 7c 
 
Principal Component Loadings for Citalopram 
 
 
PC1 PC2 PC3 PC4 PC5 PC6 PC7 
Demographics 
       Age 0.372 0.505 0.107 -0.388 0.384 0.056 0.179 
Employment Status 0.191 -0.744 0.039 -0.015 -0.153 0.124 0.253 
Income to Needs 0.451 -0.421 0.067 0.093 0.181 0.053 0.297 
Overall Health Status        
Total # Phys Dx -0.454 0.570 -0.125 0.201 -0.061 -0.070 0.350 
Phys Dx (Y/N) -0.416 0.410 -0.246 0.175 -0.200 -0.295 0.283 
Lifetime MH Dx        
Dysthymia 0.139 0.359 0.052 -0.484 0.352 0.013 0.217 
Bipolar Subthreshold 0.106 0.134 0.198 0.516 -0.122 0.341 0.570 
PD 0.140 0.165 -0.492 0.411 0.142 0.344 -0.180 
PTSD -0.408 0.164 -0.276 0.073 -0.462 -0.033 0.067 
Binge Eating -0.012 0.047 -0.431 0.144 -0.133 0.279 -0.360 
K10 Survey        
Worthless 0.711 0.134 0.252 0.042 -0.197 -0.007 -0.135 
Restless 0.289 -0.144 -0.232 0.461 0.661 -0.246 0.092 
Nothing cheered you up 0.642 0.263 0.330 0.348 -0.277 -0.175 -0.205 
Everything was an effort 0.670 0.190 0.032 0.442 -0.011 -0.111 0.018 
Screening Survey        
Appetite 0.408 0.626 0.272 -0.177 -0.270 0.094 -0.036 
Txt and Substances        
Illicit Drug Use -0.223 -0.380 0.480 0.068 -0.318 -0.302 0.102 
Medications        
Total # Meds -0.674 0.053 0.466 0.236 0.323 0.099 -0.053 
TCA -0.400 0.173 0.351 0.307 0.306 -0.380 -0.319 
Anti-Convulsant -0.396 0.081 0.528 0.144 0.095 0.624 -0.122 
 
The variables with the largest loadings into each of the principal components are shown in bold. 
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Table 7d 
 
Principal Component Loadings for Paroxetine 
 
 
PC1 PC2 PC3 PC4 
Demographics 
    Age 0.301 0.248 0.590 0.470 
Lifetime MH Dx     
Bipolar Subthreshold -0.427 -0.193 -0.295 0.530 
MDD -0.132 -0.022 0.627 -0.408 
Drug Dependence -0.283 0.276 0.356 -0.263 
K10 Survey     
Hopeless 0.737 0.129 -0.320 -0.168 
Fidgety 0.714 0.085 -0.103 -0.026 
Tired 0.762 -0.045 0.164 -0.082 
Depressed 0.897 0.013 -0.090 -0.103 
Nothing cheered you up 0.800 0.261 0.092 0.013 
Everything was an effort 0.818 -0.203 -0.194 -0.011 
Screening Survey     
Anxiety 0.463 0.049 0.331 0.565 
Medications     
Total # meds -0.219 0.788 -0.326 0.043 
Anti-Psychotic -0.119 0.903 -0.058 0.004 
 
The variables with the largest loadings into each of the principal components are shown in 
bold. 
  
Table 7e 
 
Principal Component Loadings for Venlafaxine 
 
 
PC1 PC2 PC3 PC4 PC5 PC6 
Demographics 
      Age -0.057 0.763 -0.018 -0.380 -0.032 -0.118 
Lifetime MH Dx       
PTSD -0.581 0.404 0.303 0.361 -0.181 0.113 
Adult Separation 
Anxiety 
-0.429 0.094 -0.112 -0.277 -0.196 0.725 
Conduct Disorder 0.285 -0.176 0.846 -0.370 0.026 0.119 
Txt and Substances       
Illicit Drug Use 0.284 -0.366 0.237 0.461 0.026 0.202 
K10 Survey       
Hopeless 0.738 0.371 0.086 0.268 -0.087 -0.054 
Worthless 0.713 0.378 0.152 0.162 -0.047 -0.069 
Depressed 0.682 0.528 0.085 -0.088 0.041 -0.046 
Screening Survey       
Insomnia 0.535 0.102 -0.430 0.024 0.271 0.477 
Appetite 0.199 0.703 -0.147 -0.209 -0.203 0.149 
Medications       
Bupropion 0.293 -0.208 0.822 -0.399 -0.017 0.119 
Trazodone -0.543 0.235 0.119 -0.255 -0.546 -0.074 
Anti-Psychotic -0.597 0.330 0.230 -0.023 0.563 0.060 
Benzodiazepines -0.388 0.301 0.347 0.577 -0.198 -0.144 
NBH -0.340 0.306 0.105 -0.144 0.775 -0.128 
Anti-Convulsant -0.071 0.271 0.298 0.585 0.129 0.344 
 
The variables with the largest loadings into each of the principal components are shown in bold. 
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Table 7f 
 
Principal Component Loadings for Bupropion 
 
 
PC1 PC2 PC3 PC4 PC5 
Demographics 
     Income to Needs 0.206 -0.619 0.522 0.195 0.022 
Lifetime MH Dx      
Dysthymia -0.294 0.254 0.448 0.551 0.055 
PTSD -0.281 0.666 0.430 0.022 -0.009 
Social Phobia 0.548 0.426 0.193 -0.531 -0.034 
Specific Phobia 0.206 0.607 -0.370 0.359 -0.027 
Agoraphobia with PD -0.179 -0.093 -0.426 0.105 -0.732 
Medications      
Citalopram 0.802 0.026 0.023 0.015 0.013 
NBH 0.614 -0.027 -0.120 0.578 0.037 
Other -0.190 -0.045 -0.495 0.018 0.692 
 
The variables with the largest loadings into each of the principal components are shown in bold. 
 
Table 7g 
 
Principal Component Loadings for Trazodone 
 
  PC1 PC2 PC3 PC4 PC5 
Demographics 
     Age -0.687 -0.061 0.287 0.303 0.212 
Income to Needs -0.455 0.064 0.241 0.587 -0.276 
Lifetime MH Dx      
Bipolar Subthreshold 0.312 -0.474 -0.229 -0.110 -0.557 
PA 0.669 0.062 -0.247 0.324 0.005 
Adult Separation Anxiety 0.162 -0.513 -0.170 0.275 0.639 
Alcohol Dependence 0.610 0.458 0.061 0.180 -0.085 
Alcohol Abuse 0.832 0.463 0.134 0.048 0.056 
Drug Dependence 0.580 0.395 0.333 -0.004 0.307 
Drug Abuse 0.832 0.463 0.134 0.048 0.056 
K10 Survey      
Depressed -0.346 0.486 0.491 0.283 -0.401 
Screening Survey      
Appetite -0.672 0.310 0.258 0.026 0.237 
Txt and Substances      
Illicit Drug Use 0.539 0.283 -0.384 0.003 -0.048 
Medications      
Total # Meds 0.610 -0.599 0.362 0.130 -0.059 
Anti-Psychotic 0.488 -0.543 0.513 -0.256 -0.132 
Benzodiazepines 0.429 -0.503 0.099 0.681 -0.014 
NBH 0.201 -0.165 0.764 -0.362 0.110 
 
The variables with the largest loadings into each of the principal components are shown in bold. 
 
Multivariable logistic regression. A multivariable logistic regression using the PCs as 
the independent variable and effectiveness of the drug at treating sadness as the dependent 
variable found coefficients to be significant for three out of the eight PCs for fluoxetine, three 
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out of the six PCs for sertraline, four out of the seven PCs for citalopram, four out of the four 
PCs for paroxetine, four out of the six PCs for venlafaxine, three out of five PCs for bupropion, 
and three out of the five PCs for trazodone (see Table 8).  
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Table 8 
 
Multivariable Logistic Regression Results 
  Confidence Interval  Confidence Interval 
 B Lower Upper OR Lower Upper 
Fluoxetine 
 
     
Intercept 0.138 -0.392 0.668 1.148 0.676 1.951 
PC1 1.330* 0.804 1.855 3.780* 2.234 6.394 
PC2 -0.276 -0.900 0.347 0.759 0.407 1.415 
PC3 -1.995* -3.962 -0.029 0.136* 0.019 0.972 
PC4 -1.397* -2.386 -0.409 0.247* 0.092 0.664 
PC5 0.378 -0.170 0.926 1.460 0.844 2.525 
PC6 0.023 -0.286 0.331 1.023 0.751 1.392 
PC7 -0.194 -0.651 0.262 0.823 0.522 1.300 
PC8 -0.302 -0.844 0.240 0.740 0.430 1.272 
Sertraline       
Intercept 0.658* 0.218 1.097 1.930* 1.244 2.995 
PC1 0.983* 0.575 1.391 2.673* 1.777 4.020 
PC2 -0.071 -0.399 0.258 0.932 0.671 1.295 
PC3 0.433 -.00001503 0.866 1.542 1.000 2.376 
PC4 0.432 -0.204 1.069 1.541 0.815 2.912 
PC5 -0.226 -0.596 0.144 0.798 0.551 1.155 
PC6 1.083* 0.642 1.523 2.952* 1.900 4.587 
Citalopram 
      Intercept -1.105 -2.317 0.107 0.331 0.099 1.113 
PC1 1.920* 0.904 2.937 6.822* 2.469 18.851 
PC2 -0.287 -0.993 0.418 0.750 0.371 1.518 
PC3 0.170 -0.683 1.023 1.185 0.505 2.780 
PC4 -0.799* -1.295 -0.304 0.450* 0.274 0.738 
PC5 0.889* 0.036 1.741 2.432* 1.036 5.705 
PC6 1.415* 0.191 2.639 4.117* 1.211 13.995 
PC7 1.362 -0.329 3.053 3.904 0.719 21.189 
Paroxetine 
      Intercept -0.465 -1.013 0.083 0.628 0.363 1.087 
PC1 3.164* 1.819 4.508 23.662* 6.169 90.760 
PC2 -0.777* -1.536 -0.017 0.460* 0.215 0.983 
PC3 1.127* 0.632 1.623 3.088* 1.882 5.066 
PC4 -1.270* -1.871 -0.668 0.281* 0.154 0.512 
Venlafaxine 
      Intercept -0.945* -1.224 -0.665 0.389* 0.294 0.514 
PC1 -1.182 -2.800 0.436 0.307 0.061 1.546 
PC2 1.978* 0.407 3.549 7.230* 1.502 34.792 
PC3 -4.291* -6.857 -1.725 0.014* 0.001 0.178 
PC4 2.981 -0.370 6.332 19.704 0.690 562.260 
PC5 -0.952* -1.152 -0.752 0.386* 0.316 0.471 
PC6 -0.023 -0.240 0.194 0.978 0.787 1.215 
Bupropion 
      Intercept -0.264 -1.334 0.806 0.768 0.263 2.239 
PC1 3.492* 2.453 4.532 32.866* 11.623 92.933 
PC2 -1.947* -2.697 -1.197 0.143* 0.067 0.302 
PC3 -0.130 -2.701 2.441 0.878 0.067 11.487 
PC4 -2.050* -2.603 -1.497 0.129* 0.074 0.224 
PC5 0.823 -0.670 2.316 2.277 0.512 10.131 
Trazodone 
      Intercept 4.096* 0.837 7.354 60.077* 2.310 1562.636 
PC1 -7.201* -7.554 -6.848 0.001* 0.001 0.001 
PC2 3.728* 2.504 4.952 41.601* 12.234 141.460 
PC3 2.142* 0.729 3.555 8.516* 2.072 35.000 
PC4 1.363 -2.603 5.329 3.909 0.074 206.291 
PC5 2.752 -1.622 7.125 15.667 0.197 1243.001 
OR=Odds Ratio; *=result is statistically significant (p<0.05) 
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Prediction of individual response to second-generation antidepressants. The 
coefficients in Table 8 were used to create predictions of the efficacy in treating sadness for each 
of the seven drugs in two example patients (see Figure 3). Patient A is a young female with 
moderate depression and very few socioeconomic risk factors, and patient B is a middle-aged 
female with moderate to severe depression and many socioeconomic risk factors. 
 In patient A, the model predicts that sertraline has the greatest odds of being effective, 
although these odds are still less than one. In patient B, the model predicts that venlafaxine has 
the greatest odds of being effective, with an odds ratio of 2.3. 
 
Model accuracy and validity. In the training cohort, accuracy ranged from 77.4% to 
99.7%, with a mean of 84% (see Table 9). In the testing cohort, internal validity ranged from 
58.2% to 66.6%, with a mean of 62% (see Table 9). 
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Table 9 
 
Accuracy and Internal Validity of Predicted Outcomes 
 
 Training Cohort Testing Cohort 
Fluoxetine 80.1% 58.2% 
Sertraline 77.4% 60.8% 
Citalopram 83.7% 62.2% 
Paroxetine 84.4% 63.0% 
Venlafaxine 73.8% 58.8% 
Bupropion 85.5% 65.2% 
Trazodone 99.7% 66.6% 
 
Accuracy is defined using the training cohort. Internal validity is defined 
using the testing cohort. 
 
Discussion 
The purpose of this study was twofold: 1) to explore how symptom clusters impact the 
efficacy of second-generation antidepressants in treating sadness, and 2) to create a model that 
uses demographic and clinical characteristics of depression to predict the efficacy of different 
second-generation antidepressants in treating sadness. 
Symptom Cluster Associations  
 Sadness is often the primary symptom that characterizes depression, and there are also 
many secondary symptoms associated with depression, such as anxiety, fatigue, appetite changes, 
and sleep changes. Few studies have been conducted to see whether the presence or severity of 
these secondary symptoms impact a drug’s efficacy at treating sadness. This study found that 
when controlling for demographics, current mental health treatment and medications, past 
medical history, and medication compliance, fluoxetine would be less effective if the sadness is 
accompanied by high levels of anxiety, sertraline would be less effective if the sadness is 
accompanied by high levels of fatigue, and paroxetine and venlafaxine would be less effective 
when the sadness is accompanied by other symptoms of a low mood. Physicians can use these 
broad generalizations to help choose antidepressants when treating sadness.  
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Individual Predictions of Drug Effectiveness  
While the symptom clusters can be used as a generic approach to prescribing second-
generation antidepressants, a patient’s specific demographic and clinical information can be 
plugged into the model for a more individualized approach. Inputting a patient’s data into the 
model will show the odds of each drug being effective at treating sadness. These odds ratios can 
then be compared to each other to determine which specific drug has the greatest chance of being 
effective in a particular patient. The models created have a mean accuracy of 84% and a mean 
internal validity of 62%. Notably, these results are similar to a study that used machine learning 
and available clinical information, such as demographic characteristics and clinical symptoms, to 
predict treatment response to citalopram. In that study, Chekroud et al. (2016) created a model 
with a 64.6% accuracy at predicting the efficacy of citalopram, and this same model was then 
externally validated using escitalopram data from a separate study, achieving an external validity 
of 59.6%. 
Public Health Implications 
 Depression poses a high disease burden on society in terms of personal impacts, 
economic impacts, and social impacts (Thomas & Morris, 2003). Antidepressants are the 
mainstay of treatment for depression, and the use of second-generation antidepressants such as 
SSRIs, SNRIs, bupropion, and trazodone are on the rise. Currently, choosing between second-
generation antidepressants is mostly trial-and-error, so finding a more efficient and effective use 
of these antidepressants can have significant public health benefits.  
Morbidity and mortality. Depression can lead to substantial morbidity and mortality. 
The indirect costs from decreased productivity and increased morbidity account for 70-80% of 
the total cost of depression (Hawthorne, Cheok, Goldney, & Fisher, 2003). Less than one-half of 
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people obtain full remission from depression after their first adequate trial of antidepressants. 
Ineffective treatment is associated with continued symptoms, higher rates of relapse and 
recurrence, increased hospitalizations, increased suicide risk, and impaired productivity 
(Sonawalla & Fava, 2001), all of which increase morbidity of the disease. In addition, 
approximately one-third of all patients with treatment-resistant depression attempt suicide at 
least once, increasing the mortality associated with depression (Hantouche et al., 2010). A more 
effective way of choosing antidepressants has the potential to decrease the time it takes for a 
patient to achieve remission. This would decrease overall prevalence of depression, as well as the 
morbidity and mortality associated with the disease.  
Cost-effectiveness. 
 Cost. Demographic characteristics and clinical symptoms are readily accessible 
information, so the cost of obtaining and utilizing this information is minimal. This is in sharp 
contrast to pharmacogenomics (i.e., the use of genetic data to guide treatment decisions), which 
has been increasingly used as a way to individualize and optimize the choice of a second-
generation antidepressant (Rosenblat et al., 2018). Pharmacogenomics requires obtaining a DNA 
sample from a patient and then having this sample processed in a lab. This costs roughly $2,000 
(Maciel, Cullors, Lukowiak, & Garces, 2018). Although patients with insurance often do not pay 
the full $2,000, the remaining cost of this lab work is simply passed onto society. 
 Efficacy. Currently, fewer than 50% of people respond to their first treatment of 
antidepressants. Individualized treatment has the potential to increase this percentage. A meta-
analysis of four RCTs and two open-label controlled cohort studies found preliminary evidence 
that pharmacogenomics can improve response and remission rates to antidepressants (Rosenblat 
et al., 2018). The company with the largest remission rate was CNSDose with a 72% remission 
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rate. However, most of the studies in this meta-analysis were not blinded, and some of the 
observed effect could be due to placebo effect from patients knowing they are getting treatment 
tailored specifically to them. Our model, which has a mean accuracy of 84% and an internal 
validity of 62% also has the potential of improving the response to antidepressants. 
Accessibility. GeneSight is a commonly used pharmacogenetic company. While there is 
no copay for GeneSight in patients with traditional Medicare or Medicaid, a patient with private 
insurance can expect a copay of around $330 (GeneSight, 2019). Those without insurance can 
expect to pay more. This cost can be a significant barrier to access to individualized treatment. In 
contrast, using a model that combines demographic and clinical characteristics would not have 
cost as a barrier to access. In addition, pharmacogenomics requires special equipment and 
laboratories, both of which might not be available in rural areas. In contrast, demographic and 
clinical characteristics are readily accessible to all providers. 
Strengths and Limitations 
A strength of this study is that the data comes from a sample that is representative of the 
entire United States population. Many RCTs have strict inclusion and exclusion criteria, making 
it difficult to generalize the results to the general population. However, while our model should 
theoretically be applicable to the general United States population, external validity using a 
separate dataset was not tested to verify this claim. In addition, the CPES data was collected 
from 2001 to 2003, so many of the newer drugs, such as escitalopram and duloxetine, were not 
included in this study.  
Effectiveness in this study was self-reported, and patients were asked to rate the 
perceived effectiveness of the drug in treating sadness on a Likert scale. The responses were 
subsequently dichotomized into two groups: effective and ineffective. Because most other 
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studies use decreases in HAM-D and other surveys as their outcome measure, it is difficult to 
compare our results to those of other studies.  
Future studies should be conducted to include the newer drugs, use a validated survey as 
an outcome measure, and directly compare the efficacy of using demographic and clinical 
characteristics to pharmacogenetics and current standard of care.  
Conclusion 
Depression is the sixth most costly health condition in the United States, and treatment-
resistant depression contributes significantly to this cost. As such, choosing effective starting 
antidepressants has the potential to decrease the overall cost of depression to society by 10%. 
While current guidelines for choosing antidepressants is mostly trial-and-error, there have been 
some attempts at individualizing this treatment using pharmacogenomics to help guide 
antidepressant choice. However, this process is expensive and not readily accessible to all. This 
study attempted to find symptom clusters that can help guide antidepressant choice, in addition 
to creating a model that could predict efficacy of second-generation antidepressants using 
demographic and clinical characteristics, information that is readily accessible and inexpensive. 
One model was created for each of the seven second-generation antidepressants studied. 
Together, these models had a mean accuracy of 84% and an internal validity of 62%. Given that 
fewer than 50% of individuals respond to their first adequate trial of antidepressants and those 
who fail their first antidepressant contribute significantly to the overall disease burden of 
depression, our models have the potential to decrease the overall morbidity, mortality, and 
economic costs depression poses on society. 
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Appendix B: List of Competencies Met in Integrative Learning Experience 
CEPH Foundational Competencies 
Evidence-based Approaches to Public Health 
1. Apply epidemiological methods to the breadth of settings and situations in public health practice 
2. Select quantitative and qualitative data collection methods appropriate for a given public health context 
3. Analyze quantitative and qualitative data using biostatistics, informatics, computer-based programming and 
software, as appropriate 
4. Interpret results of data analysis for public health research, policy or practice 
Planning & Management to Promote Health 
7. Assess population needs, assets and capacities that affect communities’ health 
Communication 
19. Communicate audience-appropriate public health content, both in writing and through oral presentation 
 
WSU MPH Population Health Concentration Competencies 
1. Use evidence based problem solving in the context of a particular population health challenge. 
2. Demonstrate application of an advanced quantitative or qualitative research methodology. 
3. Demonstrate the ability to contextualize and integrate knowledge of specific population health issues. 
 
